Treatment of Parapsoriasis en Plaques and Mycosis Fungoides with an Oral Aromatic Retinoid (Ro 10-9359)

Souteyrand, P.; Thivolet, J; Fulton, R. A.

doi:10.1007/978-3-642-68023-6_41

Cited by 13 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic therapy with retinoids alone has produced impressive results. Our initial report of positive results in four patients now has been confirmed by 12 additional reports including 92 patients 61–73 . We recently reported our completed phase II study achieving a 44% response (CR + PR) rate in 25 patients 61 .…”

Section: Cutaneous T‐cell Lymphoma (Ctcl)mentioning

confidence: 59%

“…A recent CTCL report documented a complete response to Ro13–6298 given as salvage therapy after isotretinoin had failed 70 . Unfortunately, the four reported trials of etretinate combined with other drugs (e.g., PUVA, prednisone, and cytotoxic agents) do not clearly define the relative contribution of etretinate to response 63, 74–76 …”

Section: Cutaneous T‐cell Lymphoma (Ctcl)mentioning

confidence: 99%

See 1 more Smart Citation

Nonsurgical Treatments for Skin Cancer: Retinoids and α‐Interferon

Lippman

Shimm²,

Meyskens³

1988

The Journal of Dermatologic Surgery and Oncology

View full text Add to dashboard Cite

Retinoids, the natural and synthetic analogs of vitamin A, and alpha-interferon have been used effectively in the treatment of certain cutaneous premalignancies and malignancies. Retinoids have shown impressive activity against premalignant disorders of the skin (actinic keratoses, keratoacanthoma, epidermodysplasia verruciformis) and of other epithelial sites (oral leukoplakia, cervical dysplasia). In established basal cell skin cancers, topical retinoid treatment has produced a complete response rate of 33%, and systemic retinoids have produced an objective response rate of 51%. In advanced squamous cell skin cancers, systemic retinoids have produced a response rate of over 70%. Intralesional alpha-interferon has produced impressive responses and systemic alpha-interferon has produced a 50% objective response rate in basal and squamous cell carcinoma. Retinoid therapy and alpha-interferon have produced modest overall results in melanoma, although striking individual responses have been reported. In cutaneous T-cell lymphoma, which is notably refractory to chemotherapy, retinoids and alpha-interferon have produced responses in 60%+ and 70%+ of cases, respectively. Retinoids and alpha-interferon, either alone or in combination, offer exciting prospects for primary and neoadjuvant therapy for advanced malignancy. Retinoids also show promise as relatively nontoxic preventive and adjuvant therapy. Researchers should focus on integrating these drugs with other biological response modifiers, differentiation agents, and cytotoxic drugs for treating advanced malignancy.

show abstract

Section: Cutaneous T‐cell Lymphoma (Ctcl)mentioning

confidence: 59%

Section: Cutaneous T‐cell Lymphoma (Ctcl)mentioning

confidence: 99%

Nonsurgical Treatments for Skin Cancer: Retinoids and α‐Interferon

Lippman

Shimm²,

Meyskens³

1988

The Journal of Dermatologic Surgery and Oncology

View full text Add to dashboard Cite

show abstract

“…Molin et al [17] found in only 1 patient partial regres sion, whereas 3 patients either did not respond or became worse. Monotherapy with retinoids gave little or no response in patients with parapsoriasis en plaque and poikiloderma [16,18]. According to the present study, it seems more advantageous to try Re-PUVA in such cases.…”

Section: Discussionmentioning

confidence: 91%

Retinoids in Cutaneous T Cell Lymphomas

Mahrle¹,

Thiele²

1987

Dermatology

View full text Add to dashboard Cite

Sixteen patients – 12 with cutaneous T cell lymphoma (CTCL), 1 with Sézary syndrome, 1 with actinic reticuloid, and 2 with parapsoriasis variegata – were treated with either a new, potent arotinoid alone or with combined etretinate (Tigason®) and PUVA therapy (Re-PUVA). 92% of all patients showed a minor up to a distinct response of their skin lesions within 12.6 ± 7.4 weeks. More than 50% of the skin lesions cleared in 67% of the patients. After discontinuation of the retinoid therapy, relapses occurred in all cases within 3–10 weeks. There was no difference between the therapeutic efficacy of arotinoid alone and the Re-PUVA regimen, but the latter was less toxic.

show abstract

“…Reported in 1983, our positive pilot data with isotretinoin and many subsequent retinoid trials produced an unprecedented response rate of 62% (21% complete responses) in 92 patients [90][91][92][93][94][95][96][97][98][99][100][101]. Preliminary data from Europe have indicated significant activity with arotinoid (Rol3-6298), which produced a response rate of 84% (5/6) including four complete responses (which included isotretinoin-resistant disease) in this malignancy [100,101].…”

Section: Mycosis Fungoidesmentioning

confidence: 93%

“…Preliminary data from Europe have indicated significant activity with arotinoid (Rol3-6298), which produced a response rate of 84% (5/6) including four complete responses (which included isotretinoin-resistant disease) in this malignancy [100,101]. Four other small uncontrolled studies from Europe suggest that combining PUVA with etretinate may improve the response rate over single-agent retinoid treatment [99,[102][103][104]. Large, well-designed trials should investigate this finding further.…”

Section: Mycosis Fungoidesmentioning

confidence: 99%